Position in LYEL
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$5,882,715
-$3,143,704 QoQ
Shares Held
293,256
0.0% QoQ
Ownership
1.26%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Alphabet Inc. holds $506,403,978 across 13 Biotechnology names. LYEL ranks #10 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
3,292,525 | $320,198,056 | |
| 2 | PRME |
Prime Medicine, Inc.
|
16,562,498 | $57,637,493 | |
| 3 | MAZE |
Maze Therapeutics, Inc.
|
1,388,583 | $41,449,202 | |
| 4 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
2,823,126 | $25,266,977 | |
| 5 | RLAY |
Relay Therapeutics, Inc.
|
1,564,173 | $15,563,521 | |
| 6 | GLUE |
Monte Rosa Therapeutics, Inc.
|
684,275 | $11,256,323 | |
| 7 | VERA |
Vera Therapeutics, Inc.
|
241,264 | $9,706,050 | |
| 8 | SANA |
Sana Biotechnology, Inc.
|
2,812,500 | $8,100,000 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,882,715 | 293,256 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $9,026,419 | 293,256 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $4,762,477 | 293,256 | Shares | Defined | 2025-11-07 | |
| 2025-06-30 | $2,592,383 | 293,256 | Shares | Defined | 2025-08-01 | |
| No filing history on record for this holder in this stock. | ||||||